Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 5581-5590 Newer>

The Motley Fool April 23, 2009 Brian Orelli	Elan's Strategic Uncertainty Elan has nothing new to report yet on the strategic review that Citigroup is preparing for them.
The Motley Fool April 22, 2009 Brian Orelli	Better Than Recession-Proof The whole health-care industry may not be recession-proof, but Gilead has shown that the right combination of drugs can lead to stellar returns -- even in a down economy.
The Motley Fool April 22, 2009	3 Stocks Hitting Low Notes This pharma stock has hit bottom. Is it ready to bounce? Take a look at: Pharmaceutical Product Development...
The Motley Fool April 22, 2009 Brian Orelli	You Left Out the Kitchen Sink, KC There was something for nearly everyone in this quarter's earnings release from Kinetic Concepts. The company's three segments ran the gamut of what's possible in this economy.
The Motley Fool April 22, 2009 Brian Orelli	Illuminating Stock Option Problems Illumina's stock options are getting a little ridiculous. This problem was pointed out in the third quarter last year, and it doesn't seem to be going away.
The Motley Fool April 22, 2009 Selena Maranjian	Will Health-Care Reform Hurt Investors? The bad news here is that there's quite a bit of uncertainty around this issue, and that some health-care-focused companies may end up suffering. Read on to see who.
Chemistry World April 21, 2009 Matt Wilkinson	Survival of the fittest While the pharmaceutical and biopharmaceutical sectors in general are outperforming broader stock market trends, many early stage companies are desperately trying to conserve cash and raise money to keep going.
The Motley Fool April 21, 2009 Brian Orelli	Reworking the Broken R&D Model When it comes to drug development, it's becoming increasingly clear that competition isn't always the best thing for the industry. Collaborations will help bring drugs to the market more cheaply.
The Motley Fool April 21, 2009 Brian Orelli	Schering and Merck: A Match Made in Purgatory Until Merck can show that it's capable of growing sales again, investors should be leery of stepping in, even with the dividend yield pushing 6%.
The Motley Fool April 21, 2009 Brian Orelli	Boston Scientific Rebuilds Whether the company is a value or a value trap depends on how well the rebuilding goes this year.
<Older 5581-5590 Newer> Return to current articles.